Latest News

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration ...

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit a

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Signi...

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significan

Teva Launches New “Pivot to Growth” Strategy

Teva Launches New “Pivot to Growth” Strategy

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now...

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Avai

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding...

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Seve

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspens...

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension,

Teva to Launch New Growth Strategy at Investor Day

Teva to Launch New Growth Strategy at Investor Day

Teva Initiates Voluntary Nationwide Recall of specific Lots of FENTANYL Buccal Tablets CII Due to a ...

Teva Initiates Voluntary Nationwide Recall of specific Lots of FENTANYL Buccal Tablets CII Due to a labeling error

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10,...

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

Complete Response Letter Received for AVT02 Biologics License Application

Complete Response Letter Received for AVT02 Biologics License Application

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at th...

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 202

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program In...

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integra